Europe
EU has duty to protect public health from tobacco
https://www.theparliamentmagazine.eu/articles/opinion/eu-has-duty-protect-public-health-tobacco-0
Implementing the WHO’s framework convention on tobacco control is key to tackling the industry’s repeated legal challenges, says Nessa Childers.
As we recognise the European week against cancer, we are also marking the world health organisation’s (WHO) world no tobacco day 2015.
Because of the very much normalised existence it still enjoys in our societies, it is important to recall the WHO’s shockingly succinct description of tobacco as the only legal consumer product that kills when used exactly as intended by the manufacturer.
Past and present experience with the lobbying and litigious strategies deployed by the tobacco industry demonstrates the extreme importance of robust policymaking in the interests of public health.
Following the Irish government’s decision to introduce plain packaging legislation, which was passed this year in the face of big tobacco’s legal threats, Japan Tobacco Ireland has issued proceedings in the Irish commercial court to block the new law on the shaky grounds that it infringes the EU directive on the harmonisation of labelling and packaging.
While JTI and other major tobacco companies were unsuccessful in their prompt challenge to Australia’s 2011 pioneering plain packaging legislation in that jurisdiction’s high court, on the spurious grounds that it infringed their intellectual property rights, one of the challenging parties, Philip Morris, decided to wage battle on another front.
They took to shifting some assets around, seemingly for the express purpose of claiming grounds to challenge Australia, under an obscure investor-state arbitration clause in a trade agreement between Australia and Hong Kong.
This international arbitration challenge was launched in 2011, in parallel with the high court proceedings which proved unsuccessful under Australian law, and has locked Australia in a complex, protracted and expensive legal conflict with the tobacco company.
The current legal challenge brought by big tobacco to the Irish courts is being fought by the state on behalf of the Irish citizens in a proper court of law. The UK is likely to follow suit, as they decided to emulate the Australian and the Irish examples.
The ongoing trade negotiations between the EU and the US authorities may still result in a trade agreement with an investor-state dispute settlement clause, despite increasing public awareness and opposition to such private, parallel and pricy arbitration courts.
If the EU-US trade agreement is passed with such an arbitration clause, a new legal front is bound to open in a private arbitration forum, an opaque netherworld where the best paid legal suits stand an even better chance of ripping off the taxpayer as punishment for public interest policy that can cost big businesses big money.
The tobacco industry has demonstrated ample ability and willingness to aggressively make use of every conceivable instrument in the legal toolbox, together with the lobby firepower we witnessed during our work on the tobacco products directive in the previous legislature.
Their tactics raise disturbing questions, some of which remain unanswered and have taken on a legal life of their own in the EU court.
This why, in parliament’s environment, public health and food safety committee’s opinion for the upcoming report on transparency and integrity in the EU, I will be calling on the institutions to fully implement the WHO framework convention on tobacco control, so as to better protect public health policy from the vested interests of the tobacco industry.
About the author
Nessa Childers (S&D, IE) is a member of MEPs against cancer
Smoking gun of tobacco smuggling
http://www.irishexaminer.com/viewpoints/columnists/ann-cahill/brussels-briefing-a-weekly-round-up-of-the-most-interesting-news-from-europe-332687.html
An EU scheme that puts big tobacco firms in charge of monitoring counterfeit tobacco smuggling is about to be renewed, despite the same companies launching a court challenge to a new EU-wide system on tracking and tracing. Governments lose huge sums in tax in smuggling operations but the companies declared that just 0.5% of seized shipments in 2012 were theirs and not counterfeits.
Independent MEP Nessa Childers says the companies should not be involved in any way after courts finding them guilty of a global scheme of smuggling, fixing prices, bribing officials, and trading with terrorists. The monitoring agreements lapse next year and Ms Childers says the “farce” should end now.
The TTIP deal hands British sovereignty to multinationals
This privileging of corporate interests over democracy is only going to get worse. The Transatlantic Trade and Investment Partnership – a treaty being hammered out between the EU and the US with woefully little scrutiny – could grant companies the same legal rights as nation states, enabling them to sue elected governments in secret courts to block policies that dent future profits. And sure enough – using a similar treaty – Philip Morris sued the Australian government for the same policy. It used the same tactic against Uruguay’s government for enlarging health warnings on cigarette packages.
This legal action should be treated as a test. Do we allow major corporations – not least those profiting from human misery – to have more rights in law than people? And indeed, this could be overreach. If Big Tobacco succeeds in wrenching £11bn worth of taxpayers’ money from schools and hospitals, they may find public anger – and demands for retribution – rather hard to ignore.
EU agreement with big tobacco hides smugglers behind smokescreens
http://nessachilders.ie/2015/05/19/eu-deals-with-big-tobacco-keep-hiding-smugglers-behind-smokescreens/
Nessa Childers, MEP for Dublin, criticised the European Commission’s ongoing negotiations to renew an agreement on smuggling with the tobacco industry.
A founding member of an MEP working group set up to fight the interference of the tobacco industry in public policy making, Ms. Childers fears that the renewal of the secretive agreement does not properly address illicit trade, depriving the public purse of compensation for tax losses.
The original agreement came about over a decade ago on foot of a settlement of a lawsuit launched by the Commission and a number of EU countries against tobacco giants Philip Morris International, R.J. Reynolds and Japan Tobacco International over a number of offences related to cigarette smuggling, which cost these companies billions of Euros.
Speaking from Strasbourg this week, where the Commission addressed the European Parliament on the matter, Ms. Childers said:
“The Commission is making a serious mistake by entertaining contacts with the tobacco industry to renew these agreements, which are due to lapse next year.
“The initial agreements were born from a settlement to a case where the Commission accused three tobacco manufacturing giants of no less than being part of a global scheme to smuggle cigarettes, launder the profits of narcotics, fix prices, bribe officials and conduct illegal trade with terrorist groups.
“Yet these companies have been put in charge of monitoring counterfeiting in tobacco smuggling seizures. They pay the authorities whenever these are found to be genuine so, unsurprisingly, they have found only 0.5% of seized shipments in 2012 to be genuine.
“This state of affairs is a mockery of enforcement and, to make matters worse, never has a sample been analysed by an independent laboratory, and we know very little of the specifics behind this scheme.
“The Commission has been officially asked by Parliament to conduct a proper assessment of this scheme back in 2012 and this should have happened by now.
“So, not only has the fox been put in charge of the henhouse, but we also have no know idea about what is going on inside, and meanwhile we are mulling over extending its safekeeping role.
“What is more outrageous, is that while these talks are going on, these very same big tobacco companies are challenging the Tobacco Products Directive in the European Court, including its requirement for an EU-wide supply chain track and tracing system.”
“We should be working on how to ratify and implement the WHO Protocol to Eliminate Illicit Trade in Tobacco Products, which the Commission rightly wants the Council to do, rather than waste time with this farce.”
More must be done to stub out the scourge of tobacco use in Europe
https://www.theparliamentmagazine.eu/articles/opinion/more-must-be-done-stub-out-scourge-tobacco-use-europe
MEPs have a responsibility to reduce the EU’s 700,000 annual smoking-related deaths, argues Brian Hayes.
Cancer is one of the biggest causes of death in Europe and lung cancer accounts for a significant number of those deaths. I believe that one of our responsibilities as legislators is to tackle the largest cause of lung cancer – smoking.
Smoking is the single biggest preventable cause of cancer in Europe, causing 90 per cent of lung cancers. Every year, more Europeans die from smoking than from the combined total of car accidents, fires, drug overdoses, murders and suicides. Around 700,000 Europeans will die from smoking this year.
The passing of the EU tobacco products directive does not mark the end of the scourge of tobacco use in Europe. Quite frankly I believe we need to do more. Some member states are exceeding their obligations which I very much welcome. Ireland, my own country, despite strong objections from the tobacco industry was the first member state to pass legislation to introduce plain packaging.
Now other countries including the United Kingdom and France are following suit. Yet, the implementation of such measures could potentially be delayed as the tobacco industry intends on taking these governments to court.
Tobacco is a unique case. It is the only legal product that will kill half of its long-term users. That is why I fully support the introduction of standardised packaging in Ireland and would like to see a situation where every EU member state adopts the same position.
Australia was the first country to introduce such legislation and the evidence is clear. Dozens of studies have concluded that standardised packaging reduces the attractiveness of cigarettes, lowers the ability of packaging to mislead consumers into believing that some products are less harmful and increases the noticeability and impact of health warning messages.
Official statistics show that Australia’s smoking rate has been significantly reduced and is continuing to fall. It is now at its lowest levels since records began.
Another area where I believe we could work to discourage smoking is on the price of tobacco. In Ireland, we have increased taxation on cigarettes to approximately €10 per pack of 20 – one of the highest rates in Europe.
Repeated studies show that price is a deterring factor for smokers. In Ireland, the largest single annual decline in smoking rates was nine per cent between June 2009 and June 2010. The origins of this can be traced back to the preceding year’s budget in which a €0.50 excise duty was added to a pack of cigarettes.
Many people will disagree with my opinion and I respect that. However, we must face reality – cancer is one the biggest causes of death across the 28 member states with lung cancer accounting for a significant amount of those deaths. If we are serious about reducing our cancer rates we need to tackle the causes.
Arguments will be made that we are overregulating the tobacco industry but if we sit back and do nothing the 700,000 Europeans that die in 2015 from smoking could be a significantly higher figure in 10 years’ time.
About the author
Brian Hayes (EPP, IE) is a member of MEPs against cancer
Pill that quashes tobacco urge found in plain sight
http://www.washingtonpost.com/business/economy/pill-promises-a-safer-cheaper-way-than-chantix-to-quit-smoking/2015/05/15/8ce5590c-f830-11e4-9030-b4732caefe81_story.html

These laburnum trees growing in vast orchards in Bulgaria could be the source of a potential new stop-smoking drug that’s being tested now in the United States. (PHOTO COURTESY OF MARIA VUCHEVA /PHOTO COURTESY OF MARIA VUCHEVA )
Rick Stewart didn’t know about the laburnum trees growing in Bulgaria — and their potential to produce a drug for quitting smoking — back when he was the chief executive of the pharmaceutical company Amarin.
He was too deep inside the drug industry, a place often criticized for its short-sighted focus on profits. He had to fail first. Only then could he spot the opportunity in those yellow-flowering trees.
Now, with the help of the National Institutes of Health, Stewart is trying to introduce the laburnum-derived drug to the U.S. market. The pill works by interrupting tobacco cravings, much like Pfizer’s top-selling Chantix, but possibly without that drug’s high-profile side effects and at a much lower price. A recent run of positive studies have buoyed the pill’s prospects. Today, researchers are excited about what could be the first new treatment for smoking cessation to emerge in years.
“We need this,” said David Shurtleff, deputy director of the NIH Center for Complementary and Integrative Health, explaining why his agency is helping to get the drug approved.
But laburnum’s promise is not new. It was just overlooked — for decades — highlighting holes in how drugs are traditionally developed.
In 2007, Stewart had staked his job as the head of Amarin on a different drug. Miraxion was for treating Huntington’s Disease, and early on it showed signs of improving symptoms of the neurological disorder. But then the drug failed two late-stage trials. Investors in Amarin, a $240 million company based in New Jersey, were stunned. The company’s stock fell 80 percent. Stewart was out of a job.
“The CEO always falls on his sword,” Stewart, 56, says now.
But Miraxion did appear to help patients with Huntington’s — it just took longer than the six months allotted during the clinical trials. Yet the damage was done. This led Stewart and Anthony Clarke, who also lost his job after running the trials for Amarin, to wonder what other misunderstood drugs were out there. They went on a hunt.
“These drugs are uncared for or unwanted. They need tender loving care,” Stewart says. “And pharma, for whatever reason, can’t be bothered with them.”
They set up a tiny company outside London named Ricanto — a mash-up of their first names. They describe the firm’s focus as pharmaceutical asset optimization. They believed innovation was not limited to new drugs. Sometimes it’s just about rediscovering old ones.
Ricanto found a compounded drug used by a few European doctors for a rare autoimmune disorder and introduced it to a larger market. It then helped identify a treatment for severe childhood epilepsy and sold the drug rights to San Diego-based Zogenix in a $130 million deal.
In 2009, Stewart learned of the laburnum trees.
A co-worker told him about a company in Bulgaria named Sopharma that made a stop-smoking drug called Tabex. The pills contained cytisine, a natural compound found in the tree’s seeds. The drug was farmed from massive laburnum orchards in Bulgaria. Cytisine targeted brain receptors to block nicotine cravings. Its power had been recognized since at least the 1940s, when Russian soldiers in World War II, short on tobacco, reportedly turned to smoking the tree’s leaves. Some soldiers found they no longer needed cigarettes.
Sopharma began making the Tabex-branded cytisine pills in 1964, but they were available only in Central and Eastern Europe.
Stewart had never heard of the drug. But he was intrigued. He was also wary. Nearly 1 billion people smoke worldwide, according to the World Health Organization. Tobacco is blamed for 5 million deaths a year. A cheap, effective drug to help smokers quit would be huge. He wondered how others could have missed this opportunity.
There are only three treatment options for U.S. smokers looking to quit.
Chantix is the newest, debuting on the market in 2006. At the time, it was the first prescription drug approved for smoking cessation by the U.S. Food and Drug Administration in nearly a decade, since GlaxoSmithKline’s antidepressant Zyban. Aside from those two drugs, there also are the nicotine-replacement gums, lozenges and patches. But that’s it. The promise of treatments such as nicotine vaccines or other drugs had flamed out. Nothing new has come down the pike.
In 2008, Chantix (sold as Champix overseas) posted $846 million in worldwide sales. But that blockbuster number dropped 17 percent the next year when the FDA slapped a “black box” warning on Chantix and Zyban because of the risk of suicidal behaviors and other mental-health problems. Facing a wave of damaging publicity, Pfizer went on to settle 2,900 lawsuits for nearly $300 million. Chantix’s reputation is still suffering. Last year, it recorded $647 million in sales.
The risk of severe side effects alarmed Stewart.
Cytisine and Chantix work in similar ways. In fact, Pfizer chemists closely studied the plant product as they developed their synthetic drug. But Pfizer supercharged its derivative to increase efficacy. Stewart noted that Tabex had amassed a database of 5 million users in Eastern Europe without signs of Chantix-like side effects.
“Why aren’t we seeing the suicidality?” he recalls thinking.
One study suggested it was because cytisine is less potent. And many researchers today believe the worst side effects attributed to Chantix — such as suicidal thoughts — are unrelated to the drug. (A Pfizer study to be released later this year is expected by many to support this notion.) But stark differences between the two drugs are found in other severe reactions, including abnormal dreams, insomnia and nausea. These are rare for cytisine, but seen in up to 30 percent of Chantix users.
Stewart struck a deal with Sopharma. He wanted to get the drug approved in Western Europe and the United States. Instead of calling it Tabex, the pill would be named Extab.
But Stewart still faced a daunting problem with cytisine.
“There’s no money in it,” said Dr. Taylor Hays, director of the Nicotine Dependence Center at the Mayor Clinic in Rochester, Minn., who would love to see cytisine get a shot here. “And that’s what usually motivates people to try bringing it to market. The money is going to drive it.”
“It’s just frustrating to think that there’s something that could be helping people and we’re not using it,” said Dr. Nancy Rigotti, director of the Tobacco Treatment Unit at Massachusetts General Hospital.
A natural product like cytisine cannot be patented. That makes its market position harder to defend. And getting a drug approved requires millions of dollars. Drug companies say the cost of developing and getting approval for a new drug is $1 billion. This might explain why some companies have seen blockbuster profits with treatments for rare diseases, such as Genzyme’s drug for Goucher disease, which costs $300,000 a year.
“They’re fixated on patent protection and new drugs,” Stewart said.
Stewart is banking on two things to turn a profit with Extab. One is the limited cytisine supply. A competitor would need to plant vast orchards of laburnum trees — hundreds of thousands of them — and wait four years before the drug-containing seeds could be harvested.
The other thing is that Extab is new to the U.S. market. No one has ever tried to get it approved. So the drug would have five years of U.S. market exclusivity as a novel drug under the 1984 Hatch-Waxman Act. That’s less than the typical 20-year window for patented medicines. But it’s something.
“It’s a really old, novel drug,” Stewart says.
Still, he needed help getting the drug through the U.S. regulatory maze. He needed to get lucky. And he did.
British medical authorities offered to pay for and run a clinical trial of cytisine. In 2011, the findings were published in the New England Journal of Medicine, showing cytisine was 3.4 times more likely than placebo to help people quit smoking and stay that way for one year, on par with Chantix.
Then a review by University of Sheffield researchers compared cytisine with Chantix and concluded that while more investigation was needed, “Cytisine is estimated to be both more clinically effective and cost-effective than (Chantix).”
But the real turning point came in December, when another study was published in the New England Journal of Medicine. Researchers with New Zealand’s National Institute for Health Innovation found cytisine was superior to the nicotine-replacement gum or patch.
The drug now had two large-scale clinical trials under its belt.
But more work lies ahead.
“I’m either absolutely mad or I guess I really believe in it,” Stewart says.
European regulators and the FDA are considering what more they need, Stewart says.
In preparation, a lab in California recently started early-stage safety tests on Extab. The NIH is picking up the tab. The NIH’s Shurtleff said the agency wants to support promising drugs that don’t have a clear path to the marketplace, especially natural products.
“That’s where we come in and provide that capital,” he says.
It could take three to five more years for the FDA’s blessing. Stewart said he hopes to find a partner to help his small firm with the U.S. market. He also brushes off any suggestion that Extab would go head-to-head with Chantix, which is made by one of the world’s biggest drug firms. It’s a strategic move on his part.
“They’ll crush us,” he says.
Stewart estimated that Extab could see $400 million in annual sales worldwide five years after launch. Pfizer will notice that.
Currently, the cytisine supply comes from 100,000 laburnum trees planted in fields ringed by protective fences in Bulgaria. Stewart knows that will not be enough if all goes to plan — if the FDA approves, if Extab takes off. He will need to ramp up production.
He has plans to plant 300,000 more of those yellow-flowering trees, including some in the United States, orchards so large they would be impossible to miss.
US-Asia trade deal in tatters after senators target Chinese currency manipulation
US President Barack Obama’s ambitions to pass sweeping new free trade agreements with Asia and Europe are in tatters after Senate Democrats rebelled, having been rebuffed on their demands to curtail Chinese currency manipulation.
A vote to push through a bill on the trade deals failed on Tuesday as 45 senators voted against it, to 52 in favour. Obama needed 60 out of the 100 votes for it to pass.
Failure to secure so-called “fast track” negotiating authority from Congress represents a huge blow to the president’s top legislative priority.
White House officials dismissed the Senate vote against fast-track as a “procedural snafu” but without this crucial agreement from lawmakers to give the administration negotiating freedom, it is seen as highly unlikely that international diplomats can complete either of the two giant trade deals currently in negotiation: the Trans-Pacific Partnership (TPP) and the Transatlantic Trade and Investment Partnership (TTIP).
The Senate fast-track legislation, known as Trade Promotion Authority or TPA, was facing even tougher opposition in the US House of Representatives.
Opponents have been emboldened by the growing influence of liberal senators Elizabeth Warren and Bernie Sanders and were joined by all but one Senate Democrat in voting against moving forward with TPA.
Even Hillary Clinton, the Democratic frontrunner for the 2016 presidential race and historically a supporter of free trade, has been cautious amid growing concern over the effect of globalisation on middle-class jobs, warning against “trade for trades sake”.
But the failure to persuade even the half-dozen Democrats needed to join Republicans in the Senate is a shock reversal from earlier consensus in the finance committee, which had included an agreement to soften the impact on US jobs with Trade Adjustment Assistance (TAA).
Oregon senator Ron Wyden, who had led Democrat efforts to find a compromise with Republicans on the committee, said he had withdrawn his support because they refused to guarantee passage of another additional bill to prevent currency manipulation by China.
White House trade negotiators fear that provisions in this bill would prove impossible to introduce into trade talks at this late stage and Republicans have dismissed the issue as a wrecking tactic by Democrats.
Utah senator Orrin Hatch, the Republican sponsor of the TPA bill, accused Wyden and other Democrats of betrayal in a speech on the Senate floor.
“I am shocked that after all we have done, the bipartisan vote in committee and the importance of TPA and TAA to the president that, we now have damaging procedural mechanics that can make this impossible,” he said. “It is hard for me to believe. We had an agreement and I am concerned about that agreement being broken.”
Hatch later told reporters the issue must be resolved quickly but was uncertain of the pathway forward. The congressional drama over the TPA, he added, “creates a whole new monster set of arguments and debates that we don’t need” in negotiations over the broader Trans-Pacific Partnership.
But Democratic critics heralded the vote as a breakthrough moment.
“We need to fundamentally renegotiate American trade agreements so that our largest export doesn’t become decent paying American jobs,” said Sanders.
Business leaders expressed disappointment in the vote. The Business Roundtable, Washington’s top business lobby group, had urged the Senate to pass TPA “without delay” arguing the trade pact would support US jobs and spur economic growth.
Last week Obama chose Nike’s headquarters to call for Congress to support the deal. Nike chief executive Mark Parker has claimed the deal would allow it to create 10,000 new jobs in the US.
Source URL (modified on May 13th 2015, 8:21am): http://www.scmp.com/news/world/article/1794855/us-asia-trade-deal-tatters-after-senators-target-chinese-currency